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doi:10.1016/j.jacl.2010.05.002BACKGROUND: Reducing low-density lipoprotein cholesterol (LDL-C) is the primary goal of ther-
apy in patients with hypercholesterolemia and coronary heart disease (CHD).
METHODS: This double blind placebo-controlled study enrolled patients 18 to 75 years of agewith pri-
mary hypercholesterolemia and establishedCHDwhowere taking a stable daily dose of simvastatin 20mg.
Patients were randomized to ezetimibe/simvastatin 10/20 mg (eze/simva; n 5 56) or simvastatin 40 mg
(simva; n5 56) for 6 weeks. Percent change from baseline in LDL-C, total cholesterol, high-density lip-
oprotein cholesterol (HDL-C), and triglycerides were assessed by use of the Student t test. The percent of
patients achieving LDL-C less than 100mg/dL (,2.6 mmol/L) or less than 80mg/dL (,2.0 mmol/L) was
analyzed via logistic regression with terms for treatment, baseline LDL-C, age, and gender.
RESULTS: Baseline characteristics were similar between groups. Treatment with eze/simva combina-
tion resulted in significantly greater reductions in LDL-C, total cholesterol, and triglycerides versus
doubling the dose of simva to 40 mg (all P , .01). Significantly more patients achieved LDL-C less
than 100mg/dL (,2.6mmol/L) and less than 80mg/dL (,2.0mmol/L) with ezetimibe/simvastatinversus
doubling the dose of simva to 40mg (73.2%vs 25.0%; P, .001) for simvastatin. Changes in HDL-Cwere
similar between treatments. Both treatments were generally well tolerated.
CONCLUSION: In high-risk CHD patients with hypercholesterolemia, treatment with eze/simva com-
bination resulted in significantly greater reductions in LDL-C, total cholesterol and triglycerides, as well as
greater achievement of recommended LDL-C targets, compared with doubling the simvastatin dose to 40
mg over the 6-week period. (Clinical trial registration number: NCT00423579)
 2010 National Lipid Association. All rights reserved.Reducing the level of low-density lipoprotein cholesterol
(LDL-C) is the primary goal for therapeutic intervention in
patients with hypercholesterolemia and coronary heart
disease (CHD).1–3 The recommended LDL-C treatmentie@fastwebnet.it
d for publication May 20, 2010.
National Lipid Association. All righttarget for patients at moderately high or high risk for
CHD is less than 100 mg/dL (,2.6 mmol/L), with less
than 70 mg/dL (1.8 mmol/L) as an optional therapeutic tar-
get in the United States1,4,5; in Europe, the targets are sim-
ilar: less than 97 mg/dL (,2.5 mmol/L) with an optional
goal of less than 80 mg/dL (,2.0 mmol/L).6 The 2009 Ca-
nadian Cardiovascular Society guidelines recommend an
LDL-C target less than 80 mg/dL (,2.0 mmol/L) or a
50% reduction in LDL-C.3s reserved.
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CoA reductase inhibitors (statins) are the first line of
therapy for lowering of LDL-C. Statins have been shown
to effectively lower LDL-C7; however, a considerable num-
ber of patients receiving moderate doses of statins do not
achieve LDL-C treatment targets.6,8,9 Intensive therapy
with greater doses of statins may confer greater reductions
in LDL-C, but some patients may not tolerate high-dose
statins.10 Moreover, the incidence of abnormalities in liver
function or myopathy may increase in a dose-dependent
manner with this class of drugs;11 and even with a high
dose, treatment goals are not met in some patients.9
The use of a combination of drugs that have a dual
mechanism of action in cholesterol regulation may be an
effective means of reducing LDL-C in patients who are not
attaining targets with statin monotherapy.12,13 Treatment
with ezetimibe, a known inhibitor of cholesterol absorption,
combined with a statin results in significantly greater
reductions in LDL-C and other lipid parameters and greater
LDL-C target attainment compared with statin monotherapy
(pooled doses) in patients with hypercholesterolemia.14–19
These significantly greater effects have also been shown
with ezetimibe added to the moderate doses of statins
compared with doubling the dose of the same statin in
moderately-high risk and high-risk CHD patients and in
diabetic patients.20–22 This study assessed the lipid-altering
efficacy and tolerability of 6 weeks of treatment with
ezetimibe/simvastatin 10/20 mg versus doubling the dose
of simvastatin to 40 mg in patients with hypercholesterole-
mia and established CHDwho had not achieved the National
Cholesterol Education Program Adult Treatment Panel III
recommended LDL-C target less than 100 mg/dL while
being treated with a daily dose of simvastatin 20 mg.Methods
Study design
This was a multicenter, randomized, parallel-groups,
double-blind, placebo-controlled study conducted at 23 sites
in Italy from July 2006 toMarch 2008.The protocol (Protocol
4039) was reviewed and approved by an Independent Ethics
Committee at each participating center, and patients provided
written informed consent prior to any study-related procedure
being started. The study was conducted under the provisions
of the Declaration of Helsinki and in accordance with the
International Conference on Harmonization Consolidated
Guideline on Good Clinical Practice.
Patients
This study enrolled men and women 18 to 75 years of age
with documented CHD (including stable angina with evi-
dence of ischemia on exercise testing, history of myocardial
infarction, percutaneous transluminal coronary angioplasty,
atherothrombotic cerebrovascular disease, unstable anginaor non-Q wave myocardial infarction; symptomatic periph-
eral vascular disease) who were taking a stable daily dose
of simvastatin 20 mg for 6 weeks with good compliance
(80% of daily doses for the 6 weeks before baseline visit)
and had LDL-C concentration greater than 100 mg/dL
(.2.6 mmol/L) to 160 mg/dL or less (#4.1 mmol/L).
Patients were instructed to maintain a cholesterol-lowering
diet and an exercise program for at least 4 weeks before
screening and during the study. Patients were required to
have triglyceride concentrations less than 350 mg/dL
(,3.99 mmol/L), liver transaminases (alanine aminotrans-
ferase [ALT] or aspartate aminotransferase [AST]) and
creatine phosphokinase (CK) less than 50% above the upper
limit of normal (ULN) with no active liver disease, and
hematology, blood chemistry, and urinalysis within normal
limits. Women of childbearing potential were required to use
effective birth control.
Patients were excluded if they had class III or IV
congestive heart failure; uncontrolled cardiac arrhythmia;
recent (within 3 months of randomization) myocardial
infarction, acute coronary insufficiency, coronary artery
bypass surgery, or angioplasty; unstable or severe periph-
eral artery disease; newly diagnosed or unstable angina
pectoris; uncontrolled hypertension (treated or untreated);
uncontrolled endocrine or metabolic disease known to
influence serum lipids or lipoproteins; impaired renal
function (creatinine .2.0 mg/dL) or nephrotic syndrome;
or were taking any lipid-lowering agents, fibrates, resins or
niacins, or prescription and/or over-the-counter-drugs with
the potential for significant lipid effects (other than study
drug) or with potential drug interactions with the statins.
Randomization and blinding
Patients were randomized according to a computer-
generated randomization schedule into two treatment
sequences by the use of a 1:1 ratio to receive either eze/
simva 10/20 mg and simvastatin 40 mg placebo or eze/
simvastatin 10/20 mg placebo and simvastatin 40 mg for 6
weeks. The study medications were packaged as 1 bottle of
eze/simva 10/20 mg (active or placebo) and 1 bottle of
simvastatin 40 mg (active or placebo). Blinding was
maintained until after study completion and database
closure. Patient compliance was assessed by tablet count
returned at the end of study. Compliance less than 70% was
considered a major protocol violation.
Efficacy measures
The primary efficacy variable was the percentage change
in LDL-C from baseline after 6 weeks of treatment.
Secondary efficacy variables were the percent of patients
achieving LDL-C less than 100 mg/dL (,2.6 mmol/L) or
LDL-C less than 80 mg/dL (,2.0 mmol/L); percent change
from baseline in total cholesterol, high-density lipoprotein
cholesterol (HDL-C), and triglycerides after 6 weeks of
treatment. The basic lipid panel assessment was conducted
274 Journal of Clinical Lipidology, Vol 4, No 4, August 2010at a central laboratory (Centro Diagnostico EXACTA,
Verona, Italy). LDL-C measurements were calculated by
the Friedewald equation.23
Safety and tolerability
Adverse events were monitored at each visit and summa-
rized by system organ class and specific adverse experience
term. Laboratory tests included complete blood count, total
protein, albumin, calcium, inorganic phosphorus, fasting
plasma glucose, blood urea nitrogen, uric acid, total bilirubin,
alkaline phosphatase, ALT, AST, gamma glutamyl transpep-
tidase, serum creatinine, thyroid-stimulating hormone
(baseline only), HbA1c, sodium, potassium, chloride, CK;
and urinalysis. The analysis of laboratory parameters was
conducted at a cental laboratory (Centro Diagnostico
EXACTA, Verona, Italy).
Statistics
Estimating a common standard deviation equal to 22.0
and choosing a 5 0.05 and b 5 0.10, it was determined
that a sample size of 55 subjects in each group would
confer a 90% power to detect a treatment group difference
in LDL-C change means of 214%, assuming that the
common standard deviation was 22.0 with the use of a two-
group t-test with a 0.05 two-sided significance level.
The primary efficacy end points were assessed in the
intention-to-treat population, which included all subjects
who were randomized, had taken at least one dose of study
drug and had at least one measurement at baseline and after
the start of treatment. Percent change from baseline in
LDL-C, total cholesterol, HDL-C, and triglyceride levelsFigure 1 Flow of patients through the study. Eze/Simva 5 ezetimibe
vastatin 40 mg.were assessed with the use of the Student t test for indepen-
dent samples using an alpha of 0.05 (two-tailed) as cut-off
for significance. Percentage of patients achieving LDL-C
targets was analyzed with a logistic regression model
with terms for treatment, baseline LDL-C level, age
(,65, $65), and gender. Odds ratio estimates derived
from the logistic regression model and 95% confidence
intervals were used to quantify the treatment effect. The
safety population included all randomized patients who
took at least one dose of study drug. The incidence of
adverse events was compared between treatments by use
of the Fisher exact test with Yates correction if applicable.Results
The flow of patients through the study is summarized in
Figure 1. Of the 182 patients that were screened, 60 were
randomized to receive eze/simva 10/20 mg, and 60 were
randomized to receive simvastatin 40 mg. A total of eight
patients discontinued from the study after randomization.
Reasons for discontinuation were seven protocol violations
(four in the eze/simva group and three in the simvastatin
group), and one adverse event (simvastatin group).
Baseline characteristics are summarized in Table 1. All
patients were white, and the majority were male (53.6%
in the eze/simva group and 57.1% in the simva 40 mg
group). The mean age (6 SD) was 61 (6 8.4) years in
the eze/simva group and 62 (6 7.8) years in the simva 40
mg group. Demographic data, medical history, cardiovascu-
lar risk factors, and baseline values of all efficacy and
safety parameters were similar between the two treatment
groups. The mean baseline LDL-C was 125.9 (6 16.3)/simvastatin 10/20 mg; ITT 5 intention to treat; simva 40 5 sim-
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(6 16.6) in the simvastatin 40 mg group. Cerebrovascular
disease was the most common form of cardiovascular dis-
ease reported at baseline, with 22 (39.3%) patients in the
eze/simva 10/20 mg group and 20 (35.7%) patients in the
simva 40 mg group (Table 1).
After 6 weeks, treatment with combination eze/simva 10/
20 mg resulted in a significantly greater reduction in mean
LDL-C level compared with doubling the dose of simvastatin
to 40mg (227% vs212%: P, .001; Fig. 2). In addition, the
percentage of patients achieving LDL-C less than 100mg/dL
(,2.6 mmol/L) was significantly greater with eze/simva 10/
20 treatment versus doubling the dose of simva to 40 mg
(73% vs 25%: P , .001; Fig. 3). The odds of achieving
LDL-C less than 100 mg/dL was 8.20 in favor of eze/simva
(95%confidence interval: 3.52219.11;P, .001) andwas de-
pendent on baseline LDL-C value but not age or gender. The
percentage of subjects who achieved LDL-C less than 80mg/
dL (,2.0 mmol/L) after 6 weeks was significantly greater for
the eze/simva 10/20 group compared with the simva 40 mg
group (21% vs 4%: P5 .010; Fig. 3). The odds of achieving
LDL-C less than 80 mg/dL was 7.36 in favor of eze/simva
(95% confidence interval: 1.56234.66; P 5 .0158) and was
dependent on baseline LDL-C value, but not age or gender.
The percent reduction in total cholesterol was signifi-
cantly greater with eze/simva 10/20 mg combination treat-
ment compared with doubling simva to 40 mg after 6 weeks
of treatment (216.9% vs 27.5%: P , .001; Fig. 4). MeanTable 1 Baseline patient characteristics
Demographics
Age, Mean years (SD)
Females, n (%)
Body mass index, kg/m2, mean (SD)
Concomitant medications, n (%)
Hypertension, n (%)
Baseline lab values, mean (SD)
LDL-C, mg/dL
Total C, mg/dL
HDL-C, mg/dL
Triglycerides, mg/dL
Fasting plasma glucose, mg/dL
AST, U/L
ALT, U/L
CK, U/L
Prevalence of cardiovascular diseases, n (%)
Cerebrovascular disease
Peripheral vascular disease
Ischemic heart disease
Cerebrovascular disease + PAD
Cerebrovascular disease + ischemic heart disease
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatin
There were no significant differences between groups.% changes in triglycerides and HDL-C were similar be-
tween treatment groups (Fig. 4).
Safety and tolerability
A summary of safety results is shown in Table 2. The
proportion of patients who reported adverse events was
similar between treatment groups (P 5 .9999), with few
discontinuations caused by adverse events (only one patient
in the simva 40-mg group). No differences between groups
were observed in the number and rate of drug-related
events, which were reported in 11.75% of patients in the
Eze/Simva group and in 6.8% of patients in the Simva
group (P 5 .5269). One serious adverse event was reported
(transient ischemic attack) that was considered nondrug
related. There were no reports of increased ALT or AST
$ 3X ULN or CK $ 5X ULN, and no deaths occurred at
any time during the study in either treatment group.Discussion
The results of this study demonstrated that ezetimibe 10
mg combined with simvastatin 20 mg produced signifi-
cantly greater reductions in LDL-C and total cholesterol
compared with doubling the dose of simvastatin to 40 mg in
patients with hypercholesterolemia and CHD. Furthermore,
a significantly greater percentage of patients achievedEze/Simva
10/20 mg
(n 5 56)
Simva
40 mg
(n 5 56)
61 (8.4) 62 (7.8)
26 (46.4) 24 (42.9)
26.6 (3.2) 26.3 (2.6)
49 (87.5) 47 (83.9)
30 (50.0) 28 (46.7)
125.9 (16.3) 128.0 (16.6)
201.2 (22.6) 201.7 (19.4)
50.5 (11.4) 48.8 (9.2)
120.2 (48.4) 124.0 (41.9)
99.5 (9.7) 100.8 (13.8)
21.5 (5.4) 20.9 (4.5)
23.5 (10.1) 23.6 (7.6)
106.4 (44.6) 113.1 (45.9)
22 (39.3) 20 (35.7)
18 (32.1) 17 (30.4)
13 (23.2) 15 (26.8)
2 (3.6) 4 (7.0)
1 (1.8) 0 (0.0)
e phosphoKinase; HDL-C, high-density lipoprotein.
Figure 2 Percent change from baseline in low-density lipopro-
tein cholesterol (LDL-C) after 6 weeks of treatment. Bars repre-
sent standard error. Eze/Simva 5 ezetimibe/simvastatin 10/20 mg;
simva 40 5 simvastatin 40 mg.
Figure 4 Percent change from baseline in total cholesterol (Total
C), high-density lipoprotein cholesterol (HDL-C) and triglycerides
(TG) after 6 weeks of treatment. Eze/Simva5 ezetimibe/simvasta-
tin 10/20 mg; simva 40 5 simvastatin 40 mg.
276 Journal of Clinical Lipidology, Vol 4, No 4, August 2010National Cholesterol Education Program Adult Treatment
Panel III recommended LDL-C targets less than 100 or less
than 80 mg/dL after 6 weeks of treatment with the
combination of eze/simva 10/20 mg compared with dou-
bling the dose of simva to 40 mg. The results of this study
were generally consistent with previous studies of similar
design and duration conducted in patients with hypercho-
lesterolemia and CHD,20,21,24–28 but this study is the first to
compare these two strategies in subjects with CHD that
excluded those with diabetes.
Failure to achieve LDL-C targets is particularly marked
in high-risk patients with hypercholesterolemia and CHD.29
Moderate doses of statin may not always be sufficient for
achievement of LDL-C treatment targets,6,8,9 and high-
dose statins may not be tolerated by all patients.10
Recent investigations have reported that alterations in
cholesterol homeostasis (namely high cholesterol absorp-
tion and low cholesterol synthesis) are associated with
increased CVD risk.30 However, the search for markers that
could predict the extent of the response to statins in terms
of LDL-C reduction has not yet produced unequivocal
and clinically applicable results. The LDL-C lowering afterFigure 3 Percent of patients achieving low-density lipoprotein
cholesterol (LDL-C) , 100 mg/dL (,2.6 mmol/L) or ,80 mg/
dL (,2.0 mmol/L) after 6 weeks of treatment. Eze/Simva 5 eze-
timibe/simvastatin 10/20 mg; simva 40 5 simvastatin 40 mg.statin treatment with appropriate potency, dose and duration
is probably at present the only way to assess if a patient is a
‘‘poor responder.’’
It has been suggested that reducing cholesterol absorp-
tion with the use of ezetimibe treatment combined with
statins to lower hepatic cholesterol synthesis may be a
practical approach to intensive lipid management and goal
achievement compared with treatments that reduce synthe-
sis alone (ie, statins) in patients with hypercholesterolemia
who have not achieved LDL-C targets on statin mono-
therapy.31 This may be of particular relevance in high car-
diovascular risk patients in whom between-group LDL-C
reductions in favor of eze/simva were demonstrated in pa-
tients who were not at target on prior statin therapy.32 In
that study, the addition of ezetimibe to simvastatin 10 or
20 mg for 6 weeks resulted in an approximately two-fold
greater magnitude reduction in LDL-C and greater target
attainment compared with rosuvastatin 10 mg.32 Similarly,
the results of the present study showed a nearly two-fold
magnitude of difference between treatment groups, con-
firming the greater efficacy for lowering LDL-C and total
cholesterol through the dual mechanism of blocking choles-
terol synthesis and absorption compared with blocking
cholesterol synthesis alone.
Both treatments had similar tolerability profiles during
the study period. There were no reports of increased ALT or
AST $3X ULN nor CK $10 ULN in either treatment
group during the study. Accordingly, neither the addition of
ezetimibe to simvastatin 20 mg nor doubling the dose of
simvastatin to 40 mg resulted in reports of myopathy or
rhabdomyolysis. These results are consistent with expecta-
tions for these drugs at the doses given and with previous
trials in this patient population.24,25,33,34 Although the inci-
dence of serious adverse events was low, this study was rel-
atively small and not powered nor of sufficient duration to
assess the prevalence of rare adverse events. The Simvasta-
tin and Ezetimibe in Aortic Stenosis (SEAS) trial raised
questions about the possibility of an increase in the inci-
dence of cancer with the addition of ezetimibe to statin
therapy,35,36 although this has not been observed in data
from a large postmarketing analysis, as well as clinical
and nonclinical study databses. A meta-analysis of cancer
Table 2 Summary of safety data
Eze/Simva 10/20 mg Simva 40 mg
Number of patients (%) (n 5 60) (n 5 60) P value
With AEs 13 (21.7) 13 (21.7) NS
With treatment-related AEs 7 (11.7) 4 (6.8) NS
Discontinued due to AEs 0 1 (1.7) NS
Discontinued due to treatment-related AEs 0 0
Serious AEs 0 1 (1.7)* NS
Serious treatment-related AEs 0 0
ALT/AST $ 3!ULN 0 0
CK $ 5-10!ULN elevation 0 0
AEs, adverse events; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CK, creatinine kinase; NS, not significant; ULN, upper limit of
normal.
*Transient ischemic attack—not drug related.
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(SHARP) that included 9264 patients and Improved Reduc-
tion of Outcomes: Vytorin Efficacy International Trial
(IMPROVE-IT) with 11,353 patients demonstrated no cred-
ible evidence of any adverse effect of ezetimibe on rates of
cancer, suggesting that the observation in the SEAS trial
was a chance occurrence.37 Longer-term follow-up may
elucidate the balance of risks and benefits of combining
ezetimbe with statin therapy.
In conclusion, treatment with combination eze/simva
results in significantly greater reductions in LDL-C levels
and attainment of LDL-C targets than doubling the dose of
simvastatin. The combination treatment was generally well
tolerated. These results provide further evidence that
inhibiting dual pathways of cholesterol metabolism may
be an effective approach to LDL-C reduction and treatment
in high-risk, non-diabetic patients with hypercholesterole-
mia and CHD who have not achieved treatment targets with
statins alone. Reduced ischemic cardiovascular event risk
has been associated with decreases in lipoprotein compo-
nents after 1 year of ezetimibe plus simvastatin treatment.38
Whether these results will translate into clinical benefit in
patients at high risk of CHD awaits results of additional
outcome studies.
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